| Name | Title | Contact Details |
|---|
Founded in 2004, Direct Flow Medical®, Inc. is focused on developing novel transcatheter heart valve technologies that improve patient outcomes while reducing patient complications. The company is exploring application of its proprietary technology beyond the aortic valve, to the mitral valve and other valve anatomy. Headquartered in Santa Rosa, California, the company also has technology and manufacturing facilities in Lake Forest, California. The Direct Flow Medical TAVI system received the CE Mark in January 2013 and is currently available commercially in Europe. Company Culture: Direct Flow Medical, Inc. has a very unique corporate culture and has developed a set of principles that makes this a unique place to work. Our company is a community, and people feel best when they are proud of their community and know that it is accomplishing something worthwhile. Our employees are encouraged to get to know one another and to support one another in their achievements. We acknowledge and celebrate professional goals as well as personal milestones. The atmosphere at Direct Flow Medical, Inc. is one that supports both a sense of satisfaction from our work, and also a sense of companionship with our co-workers.
The Health & Wellness Institute is a Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hanna Boys Ctr is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Sonoma, CA. To find more information about Hanna Boys Ctr, please visit www.hannacenter.org
Our Lady of the Valley is a non-profit, non-denominational senior living community that provides assisted living, long term nursing, and skilled rehabilitation care. They strive to enhance the quality of life for their senior living residents through p...
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.